Skip to main content

Navigation group

Type at least 3 characters
831 articles

Articles

Study Protocol

Published on 14 Feb 2024

Protocol for a randomized, placebo-controlled, double-blind phase IIa study of the safety, tolerability, and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with Parkinson’s disease (ROCK-PD)

in Parkinson’s Disease and Aging-related Movement Disorders

  • Andreas W. Wolff
  • Helen Bidner
  • Yvonne Remane
  • Janine Zimmer
  • Dag Aarsland
  • Olivier Rascol
  • Richard K. Wyse
  • Alexander Hapfelmeier
  • Paul Lingor
Protocol for a randomized, placebo-controlled, double-blind phase IIa study of the safety, tolerability, and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with Parkinson’s disease (ROCK-PD)
Frontiers in Aging Neuroscience
doi 10.3389/fnagi.2024.1308577
  • 3,305 views
  • 4 citations

Original Research

Published on 05 Feb 2024

Nigral transcriptomic profiles in Engrailed-1 hemizygous mouse models of Parkinson’s disease reveal upregulation of oxidative phosphorylation-related genes associated with delayed dopaminergic neurodegeneration

in Parkinson’s Disease and Aging-related Movement Disorders

  • Lautaro Francisco Belfiori
  • Alfredo Dueñas Rey
  • Dorottya Mária Ralbovszki
  • Itzia Jimenez-Ferrer
  • Filip Fredlund
  • Sagar Shivayogi Balikai
  • Dag Ahrén
  • Kajsa Atterling Brolin
  • Maria Swanberg
Nigral transcriptomic profiles in Engrailed-1 hemizygous mouse models of Parkinson’s disease reveal upregulation of oxidative phosphorylation-related genes associated with delayed dopaminergic neurodegeneration
Frontiers in Aging Neuroscience
doi 10.3389/fnagi.2024.1337365
  • 2,491 views
  • 1 citation